{
  "id": "jak-stat-signaling-pathway",
  "title": "JAK–STAT Signaling Pathway",
  "lang": "en",
  "source_lang": "en",
  "summary": "The JAK–STAT pathway links cytokine and hormone receptors to gene regulation, controlling immunity, blood-cell development, growth, and tissue homeostasis.",
  "category": "science",
  "subcategory": "biology",
  "type": "concept",
  "aliases": [
    "Janus kinase–signal transducer and activator of transcription pathway",
    "JAK/STAT pathway",
    "Jak–STAT signaling"
  ],
  "generated_at": "2026-11-05",
  "model": "pro/gpt-6.1-sol",
  "url": "https://aiwiki.page/en/jak-stat-signaling-pathway/",
  "translations": {
    "zh-Hans": {
      "url": "https://aiwiki.page/zh/jak-stat-signaling-pathway/",
      "json": "https://aiwiki.page/zh/jak-stat-signaling-pathway.json"
    }
  },
  "sections": [
    {
      "heading": "",
      "text": "The JAK–STAT signaling pathway is a system of intracellular communication that connects many extracellular cytokines and hormones to changes in gene expression. Its central components are Janus kinases, abbreviated JAKs, and signal transducers and activators of transcription, abbreviated STATs. Receptor-associated JAKs phosphorylate STAT proteins, which then regulate genes in the cell nucleus. This relatively direct connection between cell-surface recognition and transcription distinguishes the pathway from signaling systems that depend on longer cascades of intermediate enzymes.\n\nJAK–STAT signaling is essential for antiviral defense, immune-cell differentiation, blood-cell production, growth, and several endocrine functions. Its biological effects depend on the receptor involved, the JAK and STAT family members available, and the regulatory state of the responding cell. Inherited defects can cause immunodeficiency or immune dysregulation, whereas acquired activating mutations contribute to blood cancers. These relationships have made the pathway a major subject of molecular research and a target for medicines used in inflammatory diseases and hematological malignancies."
    },
    {
      "heading": "Discovery and evolutionary distribution",
      "text": "The pathway emerged from studies of interferons, proteins originally recognized for their ability to induce resistance to viral infection. During the 1980s, researchers investigated how interferon binding at the cell surface could rapidly activate nuclear genes without requiring the synthesis of an entirely new signaling apparatus. Work by groups associated with James Darnell, George Stark, Ian Kerr, and others combined biochemical purification of DNA-binding complexes with genetic analysis of human cell lines that failed to respond to interferon.\n\nA decisive advance came from selecting mutant cells with defects in interferon responsiveness and restoring their responses by introducing functional genes. In 1992, complementation experiments identified TYK2 as a necessary component of type I interferon signaling. Parallel biochemical work identified proteins subsequently named STAT1 and STAT2 within interferon-activated transcription complexes. Studies in 1993 established requirements for JAK1 and JAK2 in particular interferon responses. Together, these results connected receptor-associated tyrosine kinases to transcription factors activated by tyrosine phosphorylation.\n\nThe name “Janus kinase” refers to Janus, the two-faced Roman deity, and reflects the presence of two related kinase-like regions in each JAK protein. One is the principal catalytic kinase domain; the other, termed the pseudokinase domain, has important regulatory functions. The abbreviation JAK had also been used informally for “just another kinase” during early characterization. As additional cytokine systems were studied, the mechanism proved to extend well beyond interferons. Growth hormone, prolactin, erythropoietin, and numerous interleukins were found to use related receptor–JAK–STAT arrangements.\n\nComparative biology subsequently showed that JAK–STAT signaling is an evolutionarily conserved metazoan system rather than a mechanism restricted to vertebrate immunity. The fruit fly Drosophila melanogaster has a comparatively compact canonical pathway involving the receptor Domeless, the JAK Hopscotch, and the transcription factor Stat92E. It participates in development, blood-cell regulation, intestinal regeneration, and host defense. Vertebrates possess expanded families of receptors, JAKs, and STATs, permitting a much larger range of ligand-specific responses.\n\nThe evolutionary distribution also places limits on generalization. STAT-like proteins occur outside animals, but the complete receptor-associated JAK–STAT arrangement is not universal among eukaryotes. Moreover, similar pathway components can support different biological processes in different organisms. Conservation of the core phosphorylation mechanism therefore does not imply conservation of every receptor, target gene, or physiological function."
    },
    {
      "heading": "Molecular architecture of receptors, JAKs, and STATs",
      "text": "Most receptors that classically engage JAK–STAT signaling belong to the type I or type II cytokine receptor families. These are transmembrane proteins whose intracellular regions lack an intrinsic tyrosine kinase domain. They instead associate with JAKs on the cytoplasmic side of the cell membrane. This distinguishes them from receptor tyrosine kinases, in which the catalytic machinery is part of the receptor itself. Cytokine receptors may contain identical subunits, different subunits, or shared signaling chains used by several ligand-binding complexes.\n\nHumans have four JAK family members: JAK1, JAK2, JAK3, and TYK2. Each contains an amino-terminal FERM domain and an SH2-like domain that contribute to receptor association, followed by the regulatory pseudokinase domain, JH2, and the carboxy-terminal catalytic kinase domain, JH1. Receptor segments traditionally called Box 1 and Box 2 help organize these interactions, although the detailed contacts differ among receptor–JAK pairs. The pseudokinase domain is not simply an inactive duplicate: it helps stabilize and regulate the catalytic domain, and mutations within it can release normal restraints on signaling.\n\nJAK expression and receptor usage are uneven. JAK1, JAK2, and TYK2 have broad distributions, whereas JAK3 expression is concentrated largely in hematopoietic cells. JAK3 associates with the common gamma chain, a receptor subunit shared by the receptors for interleukins 2, 4, 7, 9, 15, and 21. JAK2 is central to signaling by the erythropoietin, thrombopoietin, growth hormone, and prolactin receptors. These partnerships explain why blocking one JAK can influence several cytokines and why different JAK defects produce distinct physiological effects.\n\nThe seven mammalian STAT proteins are STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6. Their common architecture includes an amino-terminal interaction domain, a coiled-coil region, a DNA-binding domain, a linker, an SH2 domain, and a carboxy-terminal transactivation region. A conserved tyrosine near the carboxy terminus is central to canonical activation. Examples include Tyr701 in STAT1, Tyr705 in STAT3, and Tyr694 in STAT5A.\n\nSTAT proteins are not interchangeable despite their shared structure. Their receptor recruitment, dimerization preferences, DNA recognition, interacting partners, and transcriptional activities differ. STAT5A and STAT5B are closely related but have partly distinct biological functions; STAT2 is especially important as a component of the type I and type III interferon transcriptional complex. Alternative protein isoforms and additional modifications introduce further variation, so the familiar receptor–JAK–STAT diagram represents a common framework rather than a single invariant molecular assembly."
    },
    {
      "heading": "Receptor activation and the phosphorylation cycle",
      "text": "Canonical signaling begins when an extracellular ligand binds its receptor and establishes a productive arrangement of receptor-associated JAKs. A common textbook description is that ligand binding causes receptor dimerization, bringing two JAKs together. This is accurate for some systems but incomplete for others. Several receptors exist as preassembled dimers or higher-order complexes, and ligand binding changes their relative orientation or spacing rather than simply creating a dimer from separate monomers. Productive geometry is crucial because physical proximity alone does not guarantee kinase activation.\n\nWithin an activated receptor complex, JAKs phosphorylate regulatory tyrosines in one another’s activation loops and phosphorylate tyrosines in receptor cytoplasmic tails. Phosphorylation transfers a phosphate group from ATP to a substrate. The newly formed receptor phosphotyrosines provide docking sites recognized by STAT SH2 domains. Specificity depends not only on the phosphotyrosine itself but also on neighboring amino-acid sequences and the structural accessibility of the docking site.\n\nRecruited STAT molecules are phosphorylated by receptor-associated kinases. Their SH2 domains then recognize the phosphorylated tyrosine of a partner STAT, stabilizing an activated dimer through reciprocal interactions. Depending on the stimulus, the products include homodimers such as STAT1–STAT1 or STAT3–STAT3 and heteromeric combinations such as STAT1–STAT2. Unphosphorylated STATs can also associate before stimulation, so activation is better understood as a change in interaction state and conformation than as an absolute transition from isolated monomers to dimers.\n\nDifferent receptor systems illustrate how the same sequence of events produces distinct outputs. The interferon-gamma receptor uses JAK1 and JAK2 and predominantly activates STAT1. Type I interferon receptors associate with JAK1 and TYK2 and activate STAT1 and STAT2. The erythropoietin receptor signals principally through JAK2 and STAT5, while receptors containing the shared gp130 subunit commonly activate STAT3. These are dominant relationships, not exclusive wiring rules: additional STATs and non-STAT pathways can be recruited according to cell type and stimulation conditions.\n\nActivation can occur within minutes of ligand exposure, but the resulting biological response may last much longer. Receptor abundance, ligand concentration, receptor trafficking, kinase activity, and the rate of dephosphorylation jointly determine the signal’s strength and duration. The pathway therefore operates as a continuously regulated phosphorylation cycle. Detection of phosphorylated STAT indicates that a signaling state has been reached, but does not by itself establish which receptor initiated it or which downstream genes will respond."
    },
    {
      "heading": "Nuclear transport and transcriptional control",
      "text": "Activated STAT complexes accumulate in the nucleus through regulated interactions with nuclear transport machinery. Nuclear entry is not an entirely new capability acquired only after phosphorylation: several STAT proteins shuttle between the cytoplasm and nucleus in unstimulated cells. Activation alters their conformation, interactions, nuclear retention, and DNA binding, producing the characteristic increase in nuclear STAT signal. Importin-dependent transport contributes to this process, with details varying among STAT family members.\n\nMany STAT dimers bind related DNA sequences known as gamma-activated sequence, or GAS, elements. A commonly used representation is \\(\\mathrm{TTCN}_{2-4}\\mathrm{GAA}\\), where \\(N\\) denotes a nucleotide and the spacing varies among recognition sites. STAT1 homodimers activated by interferon-gamma are a classic example. Binding affinity and selectivity depend on the precise sequence, spacing, neighboring regulatory elements, and cooperation with other DNA-binding proteins. Consequently, a short consensus motif alone cannot reliably identify every functional STAT-regulated gene.\n\nType I and type III interferons prominently use a different complex, interferon-stimulated gene factor 3, or ISGF3. It consists of STAT1, STAT2, and interferon regulatory factor 9, abbreviated IRF9. ISGF3 binds interferon-stimulated response elements, or ISREs, and activates many antiviral genes. Its targets include members of the OAS, MX, and IFIT gene families, whose products interfere with viral replication through different mechanisms. This example shows that STAT-dependent transcription need not be mediated by a simple STAT homodimer.\n\nDNA binding takes place within chromatin, not on an unrestricted DNA template. Activated STATs recruit or cooperate with transcriptional coactivators, chromatin-modifying proteins, and the machinery responsible for transcription. Their effects depend strongly on regulatory regions already accessible in a particular cell. A STAT3 signal in a liver cell therefore encounters a different regulatory landscape from a STAT3 signal in a T lymphocyte. Lineage-defining transcription factors help establish these differences before cytokine stimulation occurs.\n\nSTAT activity can both activate and repress gene expression, although repression may occur indirectly through induced repressors or changes in competing transcriptional programs. Some STATs also form higher-order assemblies; amino-terminal interactions permit STAT5 tetramers to bind certain paired regulatory sites. Serine phosphorylation and other modifications can modify transcriptional output without replacing the central role of canonical tyrosine phosphorylation.\n\nThe first wave of target genes often includes regulatory proteins and additional transcription factors, creating secondary transcriptional responses. Thus, a gene whose expression changes hours after cytokine treatment is not necessarily a direct STAT target. Establishing direct regulation generally requires evidence that connects STAT binding, the relevant regulatory DNA, and a functional effect on transcription."
    },
    {
      "heading": "Negative regulation, signal duration, and pathway interactions",
      "text": "JAK–STAT signaling contains several mechanisms that restrain activation and restore responsiveness after stimulation. One of the most important is the suppressor of cytokine signaling, or SOCS, family. Many SOCS genes are themselves induced by STATs, creating negative feedback: signaling produces proteins that subsequently inhibit the same signaling system. SOCS proteins generally contain an SH2 domain and a SOCS box, which can help recruit ubiquitin-ligase machinery to associated proteins.\n\nSOCS1 and SOCS3 are particularly well characterized. Both can inhibit JAK activity through a kinase inhibitory region, but their recruitment differs. SOCS3 binds selected receptor phosphotyrosines and inhibits nearby JAKs, helping restrict its action to particular receptor complexes. This is important in gp130-family signaling and in the control of inflammatory responses. Other family members, including CIS, can limit signaling by competing for docking sites or facilitating turnover of signaling components. Family membership therefore does not imply one identical inhibitory mechanism.\n\nProtein tyrosine phosphatases provide another level of control by removing phosphate groups from receptors, JAKs, or STATs. Relevant enzymes include PTPN2, often called TC-PTP, and PTPN6, commonly called SHP1. Their cellular location matters: dephosphorylation of nuclear STATs can help terminate transcriptional activity, whereas receptor-associated phosphatases can limit signal initiation. Receptor internalization and degradation also change the number of signaling-competent complexes at the cell surface.\n\nProtein inhibitors of activated STAT, or PIAS proteins, were identified through their ability to restrain STAT-dependent transcription. Their actions include influencing DNA binding, recruiting transcriptional regulators, and promoting SUMO modification of selected proteins. These effects are context-dependent and extend beyond STATs. PIAS proteins, phosphatases, and SOCS proteins therefore operate at different steps rather than forming a single redundant off-switch.\n\nJAK–STAT responses are also shaped by interactions with other signaling networks. Cytokine receptors can activate RAS–MAPK and PI3K–AKT pathways alongside STATs, influencing proliferation, survival, and metabolism. STAT-regulated genes can, in turn, change receptor expression or the production of additional cytokines. A response measured in a mixed cell population may therefore include both direct signaling and secondary communication between cells.\n\nThese mechanisms make duration a biologically meaningful variable. Brief and sustained STAT activation can produce different transcriptional programs even when the same STAT is involved. Interleukin-6 and interleukin-10 both prominently activate STAT3, yet their receptor contexts and feedback regulation differ. Their contrasting effects cannot be explained by naming the activated STAT alone; receptor organization, cellular identity, and the timing of regulatory feedback must also be considered."
    },
    {
      "heading": "Physiological roles in immunity, blood formation, and endocrine function",
      "text": "JAK–STAT signaling coordinates major components of innate immunity and adaptive immunity. Type I and type III interferons induce antiviral programs, although their receptor distributions differ: type III interferon responsiveness is especially prominent at epithelial barriers. Interferon-gamma activates STAT1-dependent programs involved in macrophage activation and antimicrobial defense. These responses include changes in antigen processing, antimicrobial effector mechanisms, and communication with other immune cells.\n\nIn lymphocytes, cytokine-specific STAT activation helps regulate development, expansion, and differentiation. Interleukin-7 supports T-cell development and survival, while interleukin-15 is important for natural killer cells and several lymphocyte populations. Interleukin-2 activates STAT5 and supports both activated T-cell proliferation and the maintenance of regulatory T cells. The coexistence of these functions illustrates why a cytokine cannot always be classified simply as stimulatory or suppressive.\n\nSeveral helper T-cell programs depend on characteristic STAT combinations. Interleukin-12 activates STAT4 and promotes type 1 responses; interleukin-4 activates STAT6 and supports type 2 differentiation. STAT3 participates in responses to cytokines including interleukin-6, interleukin-21, and interleukin-23 and is important in the development and maintenance of particular interleukin-17-producing populations. These pathways cooperate with antigen-receptor signals and lineage-specific transcription factors rather than acting as independent instructions sufficient for every differentiation outcome.\n\nThe pathway is equally important in hematopoiesis. Erythropoietin activates JAK2-dependent signaling in erythroid precursors, promoting their survival and maturation into red blood cells. Thrombopoietin signals through the MPL receptor and JAK2, contributing to megakaryocyte development, platelet production, and hematopoietic stem-cell maintenance. Granulocyte colony-stimulating factor engages STAT3 and other signaling components to regulate neutrophil production and function. The dependence of several blood-cell lineages on JAK2 helps explain both the effects of activating mutations and some adverse effects of JAK2 inhibition.\n\nEndocrine examples extend the pathway’s importance beyond immunity. Growth hormone activates its receptor-associated JAK2 and prominently engages STAT5, contributing to hepatic production of insulin-like growth factor 1 and to broader growth-related transcriptional programs. Prolactin also activates JAK2–STAT5 signaling and is important for mammary-gland differentiation and milk-protein expression. Leptin uses a receptor capable of activating JAK2 and STAT3 in the regulation of energy balance.\n\nIn the liver, interleukin-6-family signaling contributes to the acute-phase response, altering synthesis of proteins such as C-reactive protein. Across these systems, JAK–STAT activity is integrated with developmental stage, nutritional state, other hormones, and tissue-specific transcription factors. Its widespread use reflects a reusable signaling architecture, not a uniform biological effect."
    },
    {
      "heading": "Inherited defects and human immune disorders",
      "text": "Human genetic disorders provide direct evidence that individual JAK–STAT components have nonredundant functions. The consequences depend on whether a variant reduces activity, increases activity, alters protein abundance, or selectively disrupts one molecular interaction. The same gene can therefore be associated with more than one disease pattern. Interpretation also depends on inheritance: a defect affecting both gene copies may differ fundamentally from a dominant variant that interferes with the normal protein or increases signaling.\n\nBiallelic loss-of-function variants in JAK3 cause a form of severe combined immunodeficiency. A characteristic immunological pattern is markedly reduced T cells and natural killer cells with B cells present, often described as \\(T^-B^+NK^-\\). This reflects JAK3’s partnership with the common gamma chain. Loss of interleukin-7 signaling disrupts human T-cell development, while loss of interleukin-15 signaling impairs natural killer-cell development. The presence of B cells does not imply normal antibody-mediated immunity because effective B-cell responses also depend on functional T-cell help.\n\nSTAT1 disorders illustrate the importance of distinguishing loss from gain of function. Complete recessive STAT1 deficiency can produce severe susceptibility to viral and mycobacterial infections. Some dominant loss-of-function variants disproportionately impair interferon-gamma responses and are associated with susceptibility to mycobacterial disease. In contrast, heterozygous STAT1 gain-of-function variants commonly cause chronic mucocutaneous candidiasis and can be accompanied by broader infectious and autoimmune manifestations. These variants often increase or prolong STAT1 phosphorylation, disrupting the balance among immune differentiation programs.\n\nDominant-negative STAT3 variants cause a major form of autosomal dominant hyper-IgE syndrome. Established features include eczema, recurrent infections, and connective-tissue or skeletal abnormalities. Impaired development of interleukin-17-producing T cells contributes to susceptibility at epithelial surfaces. Germline STAT3 gain-of-function variants produce a different disorder, characterized by early-onset immune dysregulation that can include autoimmunity, lymphoproliferation, impaired growth, and infections. Increased activity of a signaling protein is therefore not equivalent to uniformly stronger protective immunity.\n\nTYK2 deficiency can impair responses to selected combinations of interleukins and interferons, with clinical manifestations varying among genetic defects. Certain hypomorphic TYK2 variants particularly affect interleukin-23-dependent antimycobacterial immunity. STAT2 and IRF9 deficiencies disrupt interferon-stimulated transcription and are associated with susceptibility to viral infection. STAT5B deficiency can combine growth hormone insensitivity with immune abnormalities, linking endocrine and immune functions within the same pathway.\n\nThese disorders are defined through combinations of clinical findings, genetic evidence, and functional studies. A sequence variant alone does not establish whether a protein has lost function or gained function. Measurements of phosphorylation, cytokine responsiveness, transcriptional activity, and cellular development are often necessary to connect a genotype to its biological mechanism."
    },
    {
      "heading": "Oncogenic activation and blood cancers",
      "text": "Persistent JAK–STAT signaling can support malignant-cell survival, proliferation, and resistance to apoptosis. Activation may originate in the JAK or STAT proteins themselves, in upstream receptors, or in other kinases that converge on STATs. It can also be sustained by cytokines produced by malignant cells or their surrounding tissues. The presence of activated STAT in a tumor therefore does not necessarily identify a mutation in a JAK or STAT gene.\n\nA landmark discovery in 2005 was the identification of the JAK2 V617F mutation in several myeloproliferative neoplasms. This substitution replaces valine with phenylalanine at position 617 in the JH2 pseudokinase domain. It disrupts normal regulation and promotes excessive signaling through compatible cytokine receptor complexes. The mutation is found in most cases of polycythemia vera and in substantial subsets of essential thrombocythemia and primary myelofibrosis.\n\nJAK2 V617F does not produce an identical disease in every carrier. Clinical phenotype is influenced by mutant allele burden, additional mutations, the affected stem- and progenitor-cell populations, and the order in which mutations arise. Mutations in JAK2 exon 12 provide another route to JAK2 activation, particularly in a subset of polycythemia vera lacking V617F. These findings established abnormal JAK signaling as a central mechanism in several disorders of excessive blood-cell production.\n\nUpstream lesions can activate the same pathway. Activating MPL mutations affect the thrombopoietin receptor and promote JAK2 signaling. Frameshift mutations in the gene encoding calreticulin, CALR, create an abnormal carboxy-terminal sequence and enable mutant calreticulin to activate MPL-dependent signaling. Thus, CALR-mutant disease can depend on JAK2 activity even though JAK2 itself is not mutated. This distinction is important when separating a pathway dependency from the precise initiating genetic lesion.\n\nJAK and STAT abnormalities also occur in lymphoid malignancies. Rearrangements involving JAK2 can generate fusion proteins with constitutive kinase activity. Activating JAK1, JAK3, STAT3, and STAT5B variants have been identified in particular leukemias and lymphomas. STAT3 mutations are frequent in T-cell large granular lymphocytic leukemia, while STAT5B mutations occur in selected T-cell and natural killer-cell neoplasms.\n\nIn solid tumors, persistent STAT3 activation has been associated with malignant-cell programs and signaling within the tumor microenvironment. Its sources can include growth-factor receptors, inflammatory cytokines, and non-JAK tyrosine kinases. These observations do not establish that every STAT3-positive tumor has the same dependency or will respond to the same inhibitor. The relevant causal mechanism must be distinguished from a shared biochemical readout."
    },
    {
      "heading": "Pharmacological targeting and established clinical uses",
      "text": "JAK inhibitors translate pathway biology into medicines by reducing kinase-dependent signaling. Many are small molecules that compete with ATP at the catalytic kinase domain. Because the ATP-binding regions of JAK family members are related, complete selectivity is difficult to achieve. Descriptions such as “JAK1-selective” or “JAK1/JAK2 inhibitor” summarize relative pharmacological activity rather than an absolute boundary that applies at every concentration and in every cell type.\n\nRuxolitinib, a JAK1/JAK2 inhibitor, received its first United States approval in 2011 for myelofibrosis. Its clinical effects include reductions in splenomegaly and disease-related symptoms, reflecting inhibition of abnormal signaling in malignant and inflammatory compartments. Later approvals included additional indications and formulations. Its activity in myeloproliferative disease is not restricted to patients carrying JAK2 V617F, because different initiating mutations can converge on JAK-dependent signaling.\n\nTofacitinib was first approved in the United States in 2012 for rheumatoid arthritis, establishing JAK inhibition as a therapeutic approach in immune-mediated disease. Other agents include baricitinib, upadacitinib, abrocitinib, fedratinib, and pacritinib, with differing pharmacological profiles and approved uses. Ritlecitinib inhibits JAK3 and members of the TEC kinase family. The availability of several inhibitors reflects differences in disease biology, drug exposure, kinase targeting, and clinical development rather than a single interchangeable drug class.\n\nAn alternative strategy is allosteric inhibition. Deucravacitinib binds the regulatory JH2 domain of TYK2 rather than the conserved ATP-binding site in the catalytic domain. It was approved in the United States in 2022 for plaque psoriasis. This mechanism demonstrates that regulatory regions can be drug targets and can provide selectivity that is difficult to obtain through catalytic-site competition alone.\n\nThe physiological breadth of JAK signaling also explains important adverse effects. Inhibiting cytokine pathways can increase susceptibility to infections, including herpes zoster. Interference with JAK2-dependent blood-cell production can contribute to anemia or thrombocytopenia with relevant agents. Regulatory labeling for several JAK inhibitors used in inflammatory disorders includes warnings concerning serious infections, malignancy, major cardiovascular events, thrombosis, and mortality. These warnings incorporate clinical trial and postmarketing evidence; their scope is specific to products and indications.\n\nDirect STAT inhibition is a separate drug-development problem. STAT proteins lack the conventional catalytic pocket targeted in kinases, and compounds described as STAT inhibitors may act through different mechanisms or have additional targets. Investigational approaches include interference with SH2-dependent interactions, reduction of STAT RNA, targeted protein degradation, and disruption of upstream signaling. Biochemical inhibition of a STAT-related assay is not by itself evidence of an established clinical treatment."
    },
    {
      "heading": "Experimental analysis and interpretation",
      "text": "Researchers study JAK–STAT signaling at several levels: receptor organization, kinase activation, STAT phosphorylation, nuclear localization, DNA binding, and transcriptional output. Immunoblotting with phosphorylation-specific antibodies is widely used to measure activated JAKs or STATs after cytokine stimulation. Common targets include STAT1 Tyr701, STAT3 Tyr705, and STAT5 Tyr694/Tyr699. Measurements of total protein are necessary because a change in phosphorylated protein can otherwise be confused with a change in overall protein abundance.\n\nFlow cytometry with intracellular phosphoprotein staining, often called phospho-flow, measures signaling in individual cells. This is especially valuable in blood or tissue samples containing multiple immune-cell populations. Surface markers identify cell types while phospho-specific antibodies quantify their responses to defined stimuli. A population average may conceal a strong response in one subset and no response in another; single-cell measurement makes that distinction visible. Fixation timing, antibody specificity, and sample handling materially affect the result.\n\nMicroscopy can track nuclear accumulation, while reporter assays test the activity of synthetic GAS- or ISRE-containing regulatory sequences. These assays answer different questions. Nuclear localization does not prove productive transcription, and a synthetic reporter does not reproduce the complete chromatin environment of an endogenous gene. RNA sequencing measures broader transcriptional responses, but those responses can include indirect effects produced by newly synthesized regulators or secondary cytokines.\n\nChromatin immunoprecipitation followed by sequencing, together with related chromatin-profiling methods, maps genomic regions occupied by STAT proteins. Integration with chromatin accessibility and gene-expression data helps identify regulatory networks. Occupancy alone is insufficient to establish functional necessity: a bound site may be dispensable under the tested conditions, and a regulated gene may be controlled through a distant enhancer rather than its nearest STAT-binding site.\n\nGenetic perturbation provides complementary evidence. Targeted disruption using CRISPR methods, replacement with defined mutant alleles, and inducible protein depletion can test whether a component is required. Pharmacological experiments require attention to concentration-dependent selectivity and exposure time. Agreement between a drug effect and a genetic perturbation strengthens a mechanistic interpretation, while rescue with an appropriate functional construct can help distinguish specific pathway effects from broader cellular damage.\n\nStructural methods, including X-ray crystallography and cryo-electron microscopy, reveal how receptors position JAKs and how regulatory domains constrain kinase activity. Time-resolved experiments and quantitative models address a different level of organization: how ligand concentration, receptor abundance, feedback, and phosphatase activity determine response amplitude and duration. Claims about noncanonical functions, including actions of unphosphorylated or extranuclear STATs, require experiments that distinguish those activities from the effects of conventional receptor-driven transcription."
    }
  ],
  "links": [
    "cytokine",
    "gene-expression",
    "cell-nucleus",
    "interferon",
    "cell-membrane",
    "ligand",
    "adenosine-triphosphate",
    "chromatin",
    "transcription-biology",
    "transcription-factor",
    "feedback",
    "metabolism",
    "innate-immunity",
    "adaptive-immunity",
    "interleukin-two",
    "regulatory-t-cell",
    "hematopoiesis",
    "erythrocyte",
    "severe-combined-immunodeficiency",
    "apoptosis",
    "antibody",
    "flow-cytometry",
    "rna-sequencing",
    "crispr",
    "x-ray-crystallography",
    "cryo-electron-microscopy"
  ],
  "sources": [],
  "license": "https://creativecommons.org/licenses/by/4.0/"
}